Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Fabian Hansen - aVenture Research

Fabian Hansen

AddedMar 31, 2024

UpdatedOct 13, 2026

Fabian Hansen

Fabian Hansen

Co-Founder, Presight Capital

Fabian Hansen's Career

Presight Capital

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Investment FirmWest Hollywood, CA, US

Co-Founder

Angiex

Series B$32.9MCambridge, MA, US

Board Member· Board

Peptilogics

Series B$44.1MPittsburgh, PA, US

Board Member· Board

Alloy Therapeutics

Series E$168.3MWaltham, MA, US

Board Member· Board

People Similar to Fabian Hansen

Kanishka PothulaBoard Member · Relay Therapeutics

Jack NielsenBoard Member · ALX Oncology Holdings

Roy LobbBoard Member · Mercator Therapeutics

Leadership at Presight Capital

Christian AngermayerCo-Founder

Similar to Presight Capital

Undeterred CapitalLos Angeles, CA, USest. 2020Undeterred CapitalLos Angeles, CA, US · est. 2020

Undeterred Capital: A pre-seed and seed stage fund investing in early deep tech and bioscience firms.

Investment Firm1

Foresite CapitalSan Francisco, CA, USest. 2011Foresite CapitalSan Francisco, CA, US · est. 2011

Foresite Capital: A leading US venture capital & growth equity firm, headquartered in San Francisco.

Investment Firm68

Preface VenturesNew York City, NY, USest. 2021Preface VenturesNew York City, NY, US · est. 2021

Preface Ventures: A full-service investment firm, partnering with Frontier Enterprises, investing $500k-$1M in pre/seed rounds.

Investment Firm9

Outset CapitalSan Francisco, CA, USest. 2021Outset CapitalSan Francisco, CA, US · est. 2021

Outset Capital, founded in 2021, is a San Francisco-based financial services firm.

Investment Firm2

Leadership at Angiex

Paul JaminetCo-Founder

Marty J DuvallCEO

Harold DvorakCo-Founder

Similar to Angiex

AngionUniondale, NY, USTherapeuticsest. 1998AngionUniondale, NY, US · est. 1998

US-based Angion is a biopharmaceutical firm developing novel therapeutics for acute organ injuries and fibrosis.

Public · $84.3M25

Adcentrx TherapeuticsSan Diego, CA, USTherapeuticsest. 2021Adcentrx TherapeuticsSan Diego, CA, US · est. 2021

Adcentrx Therapeutics: Pioneering protein conjugate therapeutics for cancer and life-threatening diseases.

Series A · $101M31

Ingenia TherapeuticsWatertown, MA, USAntibodies, Therapeuticsest. 2018Ingenia TherapeuticsWatertown, MA, US · est. 2018

Ingenia Therapeutics: A biotech startup developing therapeutic antibodies for cancer and chronic diseases.

Series A · $11.7M12

Angiocrine BioscienceSan Diego, CA, USGene Therapyest. 2012Angiocrine BioscienceSan Diego, CA, US · est. 2012

San Diego-based Angiocrine Bioscience is a clinical-stage company using gene therapy to regenerate tissues and rejuvenate patients.

Seed · $79.1M36

Leadership at Peptilogics

Jonathan SteckbeckCo-Founder

Dietrich StephanBoard Member

Ronald MontelaroCo-Founder

Similar to Peptilogics

LactocoreNewton, MA, USPeptide Therapeuticsest. 2018LactocoreNewton, MA, US · est. 2018

Novel peptide therapeutics firm, innovating safe solutions for psychiatric, metabolic diseases.

Pre-Seed · $3M32

20n BioMalvern, PA, USPeptide Therapeuticsest. 202120n BioMalvern, PA, US · est. 2021

20n Bio, a VC-backed start-up in Malvern, PA, specializes in designing novel protein therapeutics.

Lytica TherapeuticsCambridge, MA, USPeptides, Therapeuticsest. 2019Lytica TherapeuticsCambridge, MA, US · est. 2019

Lytica Therapeutics, Inc.: A biotech firm specializing in novel peptide therapeutics development.

Decoy TherapeuticsCambridge, MA, USPeptide Therapeuticsest. 2020Decoy TherapeuticsCambridge, MA, US · est. 2020

Decoy Therapeutics: AI-driven biotech firm developing pandemic-ready drugs via peptide 'decoys'.

Public · $250k7

Leadership at Alloy Therapeutics

Alaa HalawaBoard Member

Errik AndersonBoard Member

Similar to Alloy Therapeutics

Creyon BioSan Diego, CA, USDrug Developmentest. 2019Creyon BioSan Diego, CA, US · est. 2019

Pioneering pre-clinical firm revolutionizing oligonucleotide-based drug development for on-demand medicines.

Series A · $40M67

OmniAbEmeryville, CA, USAntibody Discoveryest. 2021OmniAbEmeryville, CA, US · est. 2021

OmniAb: Your pharmaceutical partner in discovering next-generation therapeutics through diverse antibody repertoires.

Public · $70M175

AdimabLebanon, NH, USTherapeutic Antibodiesest. 2007AdimabLebanon, NH, US · est. 2007

Adimab, LLC is a biotechnology company that provides a yeast-based antibody discovery and engineering platform for biopharma partners.

Public · $45.5M149

AbCellera BiologicsVancouver, British Columbia, CAAntibody Discoveryest. 2012AbCellera BiologicsVancouver, British Columbia, CA · est. 2012

Vancouver-based AbCellera Biologics researches and develops human antibodies using proprietary technology.

Public · $889M495